BASi

2Q Revenues: $8.4 million (+21%)

2Q Earnings: $483,000 (loss of $1.2 million in 2Q10)

YTD Revenues: $16.5 million (+24%)

YTD Earnings: $793,000 (loss of $2.7 million YTD10)

Comments: For the quarter, Service revenue rose 23% to $6.4 million while Products revenues were up 17% to $2.0 million. For YTD, Service is up 25% to $12.6 million and Products are up 21% to $3.9 million. BASi president and chief executive officer Anthony Chilton remarked, "The increase in revenue reflects the success of our efforts to build business with existing clients and expand our client base, as we leverage BASi's well-established reputation for providing innovative, high quality services and products that increase efficiency and reduce the cost of taking a new drug to market. Start-ups, biotechs, generics and other new sectors of the drug development industry are especially attractive targets for our services."